Skip to content

Study · Not a test of the peptide alone · 2010

4 results

Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients.

King AB

Diabetes technology & therapeutics1 Feb 2010Cited by 6 (Europe PMC)

PMID20105039 (opens in a new tab)DOI10.1089/dia.2009.0096 (opens in a new tab)PepBankPUB-20105039
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 01HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome

    In pramlintide-treated T1DM patients, glucose fell initially with the standard insulin waveform and returned to baseline by the fourth hour.

    In plain wordsIn pramlintide-treated patients, glucose fell with the standard insulin waveform, then returned to baseline.

    Peptide
    Pramlintide (Symlin)
    Outcome
    MixedGlucose with standard waveform
    Study

    n = 9

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Glucose change 0-2 h post-meal
    ≈ −40 mg/dL
    standard bolus wave

    Source sentences

    Summary
    With ST and C waves glucose fell approximately 40 mg/dL 0-2 h post-meal and then returned to baseline by the fourth hour.
    2 context sentences
    Summary · context
    We studied the three currently available waveforms and a "modified combination wave" (MC) in pramlintide-treated patients.
    Summary · context
    Pump-treated type 1 diabetes subjects were randomized to one bolus waveform for one full day of three meals and then crossed over to the other bolus waveforms.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 02HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome

    In pramlintide-treated T1DM patients, glucose fell initially with the combination insulin waveform and returned to baseline by the fourth hour.

    In plain wordsIn pramlintide-treated patients, glucose fell with the combination insulin waveform, then returned to baseline.

    Peptide
    Pramlintide (Symlin)
    Outcome
    MixedGlucose with combination waveform
    Study

    n = 9

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Glucose change 0-2 h post-meal
    ≈ −40 mg/dL
    combination (C) bolus wave

    Source sentences

    Summary
    With ST and C waves glucose fell approximately 40 mg/dL 0-2 h post-meal and then returned to baseline by the fourth hour.
    2 context sentences
    Summary · context
    We studied the three currently available waveforms and a "modified combination wave" (MC) in pramlintide-treated patients.
    Summary · context
    Pump-treated type 1 diabetes subjects were randomized to one bolus waveform for one full day of three meals and then crossed over to the other bolus waveforms.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  3. 03HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome

    In pramlintide-treated T1DM patients, the modified combination insulin waveform produced minimal postmeal glucose change.

    In plain wordsIn pramlintide-treated patients, the modified combination insulin waveform produced minimal postmeal glucose change.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableGlucose with modified combination waveform
    Study

    n = 9

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Post-meal glucose change
    ≈ 10 mg/dL
    modified combination (MC) wave, whole post-meal period

    Source sentences

    Summary
    The MC demonstrated minimal (approximately 10 mg/dL) change during the entire post-meal period.
    2 context sentences
    Summary · context
    We studied the three currently available waveforms and a "modified combination wave" (MC) in pramlintide-treated patients.
    Summary · context
    Pump-treated type 1 diabetes subjects were randomized to one bolus waveform for one full day of three meals and then crossed over to the other bolus waveforms.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  4. 04HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome

    In pramlintide-treated T1DM patients, the square insulin waveform increased late-meal glucose after an initially isoglycemic period.

    In plain wordsIn pramlintide-treated patients, the square insulin waveform increased glucose late in the meal period.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseGlucose with square waveform
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Glucose change in late meal period
    ≈ 20 mg/dL
    square (SQ) bolus wave, increase

    Source sentences

    Summary
    Initially isoglycemic, the SQ wave increased approximately 20 mg/dL in the late meal period.
    2 context sentences
    Summary · context
    We studied the three currently available waveforms and a "modified combination wave" (MC) in pramlintide-treated patients.
    Summary · context
    Pump-treated type 1 diabetes subjects were randomized to one bolus waveform for one full day of three meals and then crossed over to the other bolus waveforms.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.